Germing U - Search Results

1

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.

Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. Among authors: germing u. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.

2

Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics.

Aul C, Giagounidis A, Germing U. Aul C, et al. Among authors: germing u. Int J Hematol. 2001 Jun;73(4):405-410. doi: 10.1007/BF02994001. Int J Hematol. 2001. PMID: 11503953 Review.

3

Evaluating the prognosis of patients with myelodysplastic syndromes.

Aul C, Giagounidis A, Germing U, Ganser A. Aul C, et al. Among authors: germing u. Ann Hematol. 2002 Sep;81(9):485-97. doi: 10.1007/s00277-002-0530-z. Epub 2002 Sep 24. Ann Hematol. 2002. PMID: 12373348 Review.

4

[Myelodysplastic syndromes. Diagnosis and therapeutic strategies].

Aul C, Giagounidis A, Germing U, Ganser A. Aul C, et al. Among authors: germing u. Med Klin (Munich). 2002 Nov 15;97(11):666-76. doi: 10.1007/s00063-002-1210-4. Med Klin (Munich). 2002. PMID: 12434275 Review. German.

5

Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.

Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, Germing U. Strupp C, et al. Among authors: germing u. Leuk Res. 2003 May;27(5):397-404. doi: 10.1016/s0145-2126(02)00220-5. Leuk Res. 2003. PMID: 12620291

6

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C. Giagounidis AA, et al. Among authors: germing u. Leukemia. 2004 Jan;18(1):113-9. doi: 10.1038/sj.leu.2403189. Leukemia. 2004. PMID: 14586479

7

The 5q- syndrome.

Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. Giagounidis AA, et al. Among authors: germing u. Hematology. 2004 Aug;9(4):271-7. doi: 10.1080/10245330410001723824. Hematology. 2004. PMID: 15621734

8

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.

Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M, Heinsch M, Aul C. Giagounidis AA, et al. Among authors: germing u. Ann Hematol. 2005 Jun;84(6):389-94. doi: 10.1007/s00277-005-1027-3. Epub 2005 Mar 23. Ann Hematol. 2005. PMID: 15785949 Clinical Trial.

9

Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion.

Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Giagounidis AA, et al. Among authors: germing u. Acta Haematol. 2005;113(2):146-9. doi: 10.1159/000083454. Acta Haematol. 2005. PMID: 15802895

10

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.

Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Giagounidis AA, et al. Among authors: germing u. Ann Hematol. 2005 Sep;84(9):569-71. doi: 10.1007/s00277-005-1054-0. Epub 2005 May 13. Ann Hematol. 2005. PMID: 15891887

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

426 results

Search Page